Table 5

Effects of patient characteristics and targeted therapy on baseline DAS28 and on annual rate of change in DAS28 both prevaccination and post vaccination in patients with PsA

Effects on baseline DAS28 (points)Effects on annual rate of change in DAS28 (points/year)
P valuePrevaccinationP valuePost vaccinationP value
Gender (ref. woman)−0.790±0.105<0.0010.002±0.0210.9220.050±0.5120.922
Age at vaccination (per year)0.007±0.0050.115−0.001±0.0010.3760.025±0.0230.275
Targeted therapy at vaccination (ref. TNF-i)0.302±0.0910.001−0.107±0.031<0.0010.617±0.5490.261
  • *Plus-minus values represent means±SE.

  • PsA, psoriatic arthritis; ref., reference; TNF-i, tumour necrosis factor inhibitor.